SCHEMBL702945

SCHEMBL702945

CC12CCCN1C(=O)N(Cc1ccccc1)C2

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
GAA P10253 1/20 0.44
OPRM1 P35372 4/20 0.43
OPRL1 P41146 3/20 0.43
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP2D6 P10635 6/20 0.42
POLB P06746 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KCNH2 Q12809 2/20 0.42
DRD3 P35462 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
ELANE P08246 1/20 0.41
RIPK1 Q13546 1/20 0.40
CYP3A4 P08684 3/20 0.40
TSHR P16473 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL704843 0.87 ERCC1 (0.42) KMT2AMEN1KCNH2DRD3
SCHEMBL1116555 0.87 SIGMAR1 (0.44) KMT2AMEN1GAAOPRM1OPRL1
SCHEMBL705534 0.87 MAPT (0.50) KMT2AMEN1CYP2C9CYP2C19KCNH2
SCHEMBL704332 0.84 DRD2 (0.47) KMT2AMEN1OPRM1OPRL1CYP2D6
SCHEMBL1116570 0.77 MAOB (0.43) CYP2C9CYP2C19KCNH2DRD3SIGMAR1
SCHEMBL1116546 0.77 KCNH2 (0.43) KMT2AMEN1CYP2D6CYP2C19KCNH2
SCHEMBL704329 0.74 KDM4E (0.45) KMT2AMEN1OPRM1CYP2D6CYP2C9
SCHEMBL706155 0.70 HSD11B1 (0.43) KMT2AOPRM1OPRL1CYP2D6CYP2C9
SCHEMBL6734594 0.70 KMT2A (0.66) KMT2AMEN1GAADDB1CRBN
SCHEMBL6732110 0.70 KMT2A (0.66) KMT2AMEN1GAADDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280970-B1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP claimed
US-8124636-B2 Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US claimed
EP-2280970-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-02-09 EP claimed
WO-2009132986-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO claimed
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HOFFMANN-LA ROCHE, INC. 2009-11-05 US claimed
EP-2280970-B1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
US-8124636-B2 Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
EP-2280970-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-02-09 EP disclosed
WO-2009132986-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO disclosed
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HOFFMANN-LA ROCHE, INC. 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HSD11B1, HSD17B1, HSD17B11 KMT2A 2297/4885MEN1 507/4885GAA 2909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.